Sugar-coated drug news

One of the great risks of buying shares in a small biotechnology company is that the value of that stock so often depends on the prospects of a single drug. News of progress drives the price through the roof, but disappointment can punish a stock with panic prices. (Full article: 698 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

• $4.95 1 article
• $9.95 4 articles
• $25.95 Monthly